ACE and diabetic kidney disease: However, formulation redesign still faces challenges at the clinical translation level: research on using lysosomal conjugates for the targeted treatment of diabetic kidney disease remains scarce, and there is a lack of data on combined use with commonly used DKD therapies such as SGLT2 inhibitors and ACE inhibitors.